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Abstract
Background: RPS15A is a ribosome protein that is highly conserved in many organisms from yeast to human. A
number of studies implied its role in promoting cancer cell growth.
Methods: Here, we firstly conducted RPS15A gene expression analysis in brain cancer using Oncomine database
and found RPS15A was remarkably overexpressed in glioblastoma (GBM) compared with that in normal tissues.
Then, the expression of RPS15A was specifically silenced in GBM cell line U251 using lentiviral-mediated RNA
interference technique. We further investigated the effect of RPS15A knockdown in U251 cells using MTT assay,
colony formation test, and flow cytometry analysis. We detected the protein level of Bcl-2 and poly (ADP-ribose)
polymerase (PARP) as well as activation of caspase-3.
Results: Our results showed that the knockdown of RPS15A could inhibit cancer cell growth and colony formation
in vitro, as well as induced cell cycle arrest at G0/G1 phase and cell apoptosis. In addition, Western blot analysis
indicated that the knockdown of RPS15A could significantly inhibit bcl-2 and activate caspase-3 and PARP.
Conclusions: Our findings suggest RPS15A may play an important role in the progression of GBM and lentiviral-
mediated silencing of RPS15A could be an effective tool in GBM treatment.
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Background
Glioma is the most common and most aggressive malig-
nant brain tumor in the human central nervous system.
According to histological progression, gliomas are classi-
fied into four grades, including low-grade astrocytomas
(grade I–II), anaplastic astrocytomas (grade III), and
glioblastoma (GBM, grade IV) [1, 2]. As a frequent form
of malignant glioma [3], GBM is invariably lethal for pa-
tients at most 2 years following diagnosis [4]. Current
standard treatment for patients with GBM is concurrent
TMZ and radiotherapy followed by six maintenance cy-
cles of adjuvant chemotherapy to improve progression-
free survival and overall survival [5]. Despite the
standard of care therapy, recurrence rates remain
higher in patients with GBM. Therefore, it is urgent to
identify new molecular targets to improve the prognosis
against human GBM.
Ribosome is the fundamental translational machinery
for protein synthesis from messenger RNAs. In eukary-
otes, a mature ribosome consists of 60S and 40S sub-
units [6]. Ribosome biogenesis and protein translation
are fine-tuned to match the cell growth rate, prolifera-
tion, and differentiation during development. However,
this type of regulation is abnormal in cancer cells [7].
Several tumor suppressors could inhibit tumor cell
growth by affecting ribosome biogenesis [8]. On the
other hand, oncogenes often stimulate cell growth and
proliferation by enhancing ribosome biogenesis in cancer
cells [9]. RPS15A, ribosomal protein s15a, is one of the
subunits of the 40S ribosomal protein [10, 11]. To data,
there are several preliminary studies which show that
down-regulation of RPS15A suppresses proliferation of
lung cancer cells, osteosarcoma cells, and hepatic cancer
cells in vitro [12–14]. Despite the ubiquitous presence
and important functions of ribosomal complex, the role
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of ribosomal protein RPS15A in GBM cells remains not
to be fully understood.
Herein, we aimed to investigate the effect of RPS15A
knockdown in GBM progression. We firstly found the
messenger RNA (mRNA) levels of RPS15A were signifi-
cantly up-regulated in glioma compared that in normal
tissues using the datasets from Oncomine database.
Functional analysis showed knockdown of RPS15A obvi-
ously suppressed cell proliferation in U251 by inducing
cell cycle arrest and apoptosis. More interestingly, we
found RPS15A knockdown induced apoptosis through
cell intrinsic mitochondria pathway. Our results sug-
gested a prominent role of RPS15A in GBM cell pro-
liferation and provide a new insight to a potential
therapeutic target for GBM.
Methods
Cell lines and culture
The human GBM cell line U251 and the human embry-
onic kidney cell line 293T (HEK293T) were purchased
from Cell Bank of Chinese Academy of Science (Shanghai).
Cells were cultured in DMEM (Hyclone) supplemented
with 10 % FBS (Biological Industries) at 37 °C in an
incubator containing 5 % CO2.
Construction of RPS15A short hairpin RNA containing
lentivirus
For the RNA interfering experiment, two short hairpin
RNA (shRNA) sequences were designed against the
RPS15A gene (NM_001019): shRPS15A-1, 5′-GTGC
AACTCAAAGACCTGGAACTCGAGTTCCAGGTCTT
TGAGTTGCACTTTTT-3′ and shRPS15A-2, 5′-GCA
TGGTTACATT-GGCGAATTCTCGAGAATTCGCCA
ATGTAACCATGCTTTTT-3′). The control shRNA
(shCon) sequence was 5′-GCGGAGGGTTTGAAAGAA
TATCTCGAGATATTCTTTCAAACCCTCCGCTTTTT
T-3′. Each nucleotide sequence was synthesized and
inserted into pFH-L shRNA expressing vector. For lenti-
viral production, recombinant plasmid described above
and pHelper plasmids (pVSVG-1 and pCMVΔ8.92) were
co-transfected into HEK293T cells using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instruc-
tion. After 72 h, virus supernatant was harvested and con-
centrated by ultracentrifugation (4000g at 4 °C) for
10 min.
Cell infection
For cell infection, U251 cells were seeded at a density of
50,000 cells per well in six-well plates and transduced
with constructed lentiviruses (shCon, shRPS15A-1, and
shRPS15A-2) at a multiplicity of infection of 40. After
72-h infection, the infection efficiency was determined
by observing the green fluorescence protein (GFP)
expression under a fluorescence microscope.
Quantitative PCR analysis
After 6-day infection, total RNA was isolated from cells
by using the Trizol reagent (Invitrogen), according to
the manufacturer’s protocol. Reverse transcribed was
performed Bio-Rad Connect Real-Time PCR (polymer-
ase chain reaction) platform (Bio-Rad Laboratories Inc,
Hercules, CA, USA) using an SYBR Green Master Mix
Kit. Data were analyzed using the 2ΔΔCt method, and the
levels of mRNA were normalized to β-actin. The PCR





Western blot analysis was done 5 days post infection.
Proteins were extracted from cells using 2× SDS sample
buffer (100 mM Tris-HCl (pH 6.8), 10 mM EDTAm 4 %
SDS, 10 Glycine. A total of 30 ug proteins were sepa-
rated in 12 % SDS-PAGE and transferred to PVDF
membranes. The membranes were incubated with pri-
mary antibodies (rabbit anti-RPS15A, 1:1000, Ab175054,
Abcam; rabbit anti-caspase-3, 1:500, #9661, Cell signal-
ing; rabbit anti-poly (ADP-ribose) polymerase (PARP),
1:1000, #9542, Cell signaling; rabbit anti-bcl-2, 1:1000,
#2876, Cell signaling; rabbit anti-GAPDH, 1:500000,
#2876, Cell signaling) for 1 h at room temperature
followed by incubation with secondary antibody goat
anti-rabbit HRP (Santa Cruz) at room temperature for
1 h. The bands were visualized using an ECL kit (Beyo-
time). Protein bands were quantified using Gel-pro
analyzer software (MediaCybernetics). GAPDH was used
as the reference control.
MTT assay
Cells were seeded in a 96-well plate with 2500 cells per
well. Growth curve and MTT assay was carried out 96 h
post transduction of virus. Briefly, MTT solution was
added to each well, followed by 4 h of incubation at 37 °C.
Then, cells were washed and dissolved in acidic isopropa-
nol (10 % SDS, 5 % isopropanol, and 0.01 mol/L HCl) for
10 min. Cell density was measured at 595 nm using the
microplate reader using enzyme-linked immunosorbent
assay. The cell growth curves were drawn according to
the OD values.
Colony formation analysis
Cells were seeded at the density of 500 cells per well in a
six-well plate. After 96 h infection with shRNA virus,
followed by additional eight days of incubation, cells
were washed with PBS twice, fixed with absolute metha-
nol for 15 min. Then, fixed cells were stained with 1 %
crystal violet for 20 min. After cleaning with PBS, col-
onies were counted under light microscope.
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Cell cycle and apoptosis analysis
Cells were seeded in a 6-cm dish at 100,000 cells per
well. Four days after infection with lentivirus, the cells
were fixed with pre-cooled 70 % ethanol at 4 °C over-
night and incubated with 1 mg/ml RNase A (QIAGEN)
for 30 min at 37 °C. Then, cells were added propidium
iodide (50 ug/mL, ebioscience) at 4 °C for 30 min to
stain DNA. The DNA content of cells was determined
by a FACS Calibur II sorter and Cell Quest FACS system
(BD Biosciences).
For cell apoptosis analysis, cells were harvested after
3-day infection with lentivirus and resuspended in
100 ul 1× binding buffer (ebioscience). Then, cells
were stained with 2 uL Annexin V-APC (20 ug/ml;
ebioscience) for 15 min on ice. Samples were diluted to
400 uL and added 1 uL 7-AAD (50 ug/ml; ebioscience)
before detection on FACS Calibur II sorter and Cell Quest
FACS system (BD Biosciences).
Statistical analysis
All experiments were at least repeated in triplicate. All
data were analyzed using GraphPad Prism software and
expressed as the mean ± standard deviation (SD) of three
independent experiments. Comparisons between groups
were conducted by Student’s t test. The p value <0.05
was considered as statistically significant.
Results
RPS15A is overexpressed in GBM
In order to evaluate the differential expression of
RPS15A in GBM, we used the Oncomine database
(www.oncomine.org), a cancer microarray database of
genome-wide expression analysis [15]. A quick search of
RPS15A gene in GBM revealed that this gene was up-
regulated in several types of GBM, including anaplastic
oligoastrocytoma [16, 17], glioblastoma [16, 18], oligo-
dendroglioma [19], and diffuse astrocytoma [20] vs.
normal tissues (Table 1). The comparison showed an
average increase of one- to sixfold in RPS15A expression
in GBM compared to normal tissues. Therefore, we con-
cluded that RPS15A might play an important role in
GBM progression. Thus, we focused on this particular
gene in following studies by using U251, a cell line
derived from a malignant glioblastoma.
RPS15A gene knockdown in U251 cells
To investigate the biological function of RPS15A in glio-
blastoma cells, we constructed two individual shRNA vec-
tors for RPS15A knockdown using lentiviral vectors
carrying green fluorescent protein (GFP). Both control
vectors (shCon) and two target vectors (shRPS15A-1 and
shRPS15A-2) showed good infection rates 72 h post infec-
tion in U251 cells, determined by a fluorescence micros-
copy of the GFP expression (Fig. 1a, b). We performed
RT-PCR and western blot to evaluate the efficiency of
shRNA knockdown of RPS15A. As shown in Fig. 1c, d,
both of two target shRNAs showed significant reduction
of RPS15A mRNA compared to the shCon (p < 0.001).
Western blot confirmed that, at protein level, target
shRNAs efficiently knocked down RPS15A expression in
U251 cells (Fig. 1e). Together, these results suggested that
we successfully constructed RPS15A knockdown cell
model, which could be applied to the following studies.
RPS15A knockdown affects cell proliferation and colony
formation ability
We next examined the effect of RPS15A on cell prolifer-
ation and viability. We measured cell proliferation by
MTT assay, a colorimetric assay assessing cell metabolic
activity depending on NADPH oxidoreductase enzymes,
over the course of 5 days. As shown in Fig. 2a,
shRPS15A-treated cells showed significant inhibition of
cell proliferation compared to cells treated with shCon
(p < 0.001). We also did colony formation assay with
cells treated by shCon vs. shRPS15A. As shown in
Fig. 2b, c, shRPS15A-treated cells failed to form any
colony, whereas shCon-treated cells can form colonies
Table 1 RPS15A differential transcript expression in human glioblastoma extracted from multiple studies in the Oncomine database
Study Comparison (specimen number in each group) Fold change p value
Bredel M et al. Anaplastic oligoastrocytoma (6) vs. normal(4) 2.125 0.005
Bredel M et al. Anaplastic oligodendroglioma (3) vs. normal (4) 2.337 0.004
Bredel M et al. Glioblastoma (5) vs. normal (4) 1.916 6.64E−04
Bredel M et al. Oligodendroglioma (27) vs. normal (4) 2.014 0.006
French PJ et al. Anaplastic oligodendroglioma (23) vs. normal(6) 2.373 4.09E−05
Murat A et al. Glioblastoma (80) vs. normal(4) 1.985 1.51E−08
Shai R et al. Oligodendroglioma (3) vs. normal (7) 5.803 5.49E−06
Sun L et al. Diffuse astrocytoma (7) vs. normal (23) 2.163 8.40E−07
TCGA Brain glioblastoma (542) vs. normal (10) 1.408 7.04E−04
TCGA The Cancer Genome Atlas-Glioblastoma Multiforme Gene Expression Data (http://tcga-data.nci.nih.gov/tcga/)
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naturally (p < 0.01). Therefore, RPS15A could promote
cell viability and proliferation ability.
RPS15A plays a role in cell cycle progression in U251 cells
Inhibition of cell proliferation could occur at any stage
of the cell cycle. To investigate the mechanisms of the
U251 cell proliferation inhibition induced by shRPS15A,
we used flow cytometry to examine the cell cycle progres-
sion under the treatment of shCon or shRPS15A (Fig. 3a).
We found that 72 h after shRNA treatment, shRPS15A-
treated cells showed significantly reduced cells in S phase
compared to shCon-treated cells (p < 0.001); instead, there
were more cells accumulated in G0/G1 phase (p < 0.001)
after shRPS15A infection, but no significant difference
was found in G2/M phase (Fig. 3b). This cell cycle results
strongly indicated that knockdown of RPS15A arrested
cell cycle at G0/G1 phase, which means RPS15A plays an
important role in cell cycle progress from G1 to S phase.
RPS15A knockdown induces apoptosis in U251 cells
To further investigate the effect of RPS15A on cell apop-
tosis, Annexin V combined with 7-Aminoactinomycin D
(7-AAD) staining was used to distinguish apoptosis
(Fig. 4a) between early and late stages of apoptosis based
on the exposure of phosphatidylserine to the surface of
cell apoptosis [21]. We found that knockdown of
RPS15A significantly induced cell early (Annexin V+/7-
AAD−) and late apoptosis (Annexin V+/7-AAD+) in
U251 cells (Fig. 4b, p < 0.001).
We further extended our study to investigate the path-
way through which RPS15A knockdown induced apop-
tosis. Apoptosis is typically induced through two distinct
signaling pathways: the death receptor pathway and
mitochondrial pathway [22]. Because RPS15A is a cyto-
solic protein, we hypothesized it affected mitochondria
pathway, in which bcl-2, caspase 3, and PARP are critical
components. Thus, we carried out Western blot analysis
to determine the expression of these three proteins in
shRPS15A-treated cells. As shown in Fig. 4c, the anti-
apoptotic and mitochondria localized protein Bcl-2 was
down-regulated in U251 cells after RPS15A knockdown.
The expression levels of cleaved caspase-3 and PARP
were up-regulated in U251 cells following shRPS15A in-
fection. This result indicated that RPS15A knockdown
activated the mitochondrial pathway of apoptosis. What
is more, shRPS15A-1 showed more strong effect on
Fig. 1 Verification of RPS15A silencing in U251 cells after shRPS15A infection. a, b Infection efficiency was assessed by counting GFP-positive cells
with fluorescence microscopy. c, d The mRNA levels of RPS15A in U251 cells with three treatments (shCon, shRPS15A-1, and shRPS15A-2) measured by
qPCR analysis. The experiment was performed in triplicate and repeated three times. e The protein levels of RPS15A in U251 cells with three treatments
(shCon, shRPS15A-1, and shRPS15A-2) determined by Western blot analysis. ***p < 0.001
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apoptosis induction than shRPS15A-2. Taken together,
we found that RPS15A knockdown induced U251 cells
apoptosis through mitochondrial pathway.
Discussion
RPS15A encodes a 40S ribosomal protein S15a, one of
the components of the 40S subunit in human [23]. Ribo-
somes are required for basic cellular functions, especially
for cancer cells, whose growth and proliferation are
uncontrolled, thus demand a large amount of protein
synthesis [7]. GBM is invariably lethal glioma character-
ized by extremely high aggressiveness. However, little is
known about the biological function of ribosome forma-
tion in GBM progression. In this study, we firstly evalu-
ated the relative expression of RPS15A in glioma tissues
and normal tissues and found it was significantly up-
regulated in GBM tissues compared with that in normal
tissues. To further investigate its role in GBM, the func-
tional role of RPS15A in human GBM cell growth was
studied by RNAi-mediated knockdown. Our results
Fig. 3 Lentivirus-mediated knockdown of RPS15A blocks the cell cycle progression of U251 cells. a Representative images of cell cycle distribution of
U251 cells with two treatments (shCon and shRPS15A-2) analyzed by flow cytometry using PI staining. b Statistical analysis of the respective proportion
of U251 cells in the G0/G1, S, and G2/M phases. The experiment was performed in triplicate and repeated three times. ***p < 0.001
Fig. 2 Lentivirus-mediated knockdown of RPS15A suppresses cell viability and the colony formation ability of U251 cells. a Growth curve of U251
cells with three treatments (shCon, shRPS15A-1, and shRPS15A-2) determined by MTT assay. b Representative images of colonies formed in U251
cells with three treatments (shCon, shRPS15A-1, and shRPS15A-2) measured by the colony formation assay. c Statistical analysis of colony formation
ability as shown. The experiments was performed in triplicate and repeated three times. **p < 0.01, ***p < 0.001
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showed knockdown of RPS15A remarkably suppressed
U251 cell growth, possibly due to induction of cell cycle
arrest and apoptosis.
Similar effects of RPS15A were demonstrated in previ-
ous studies in other cancer types [13, 24]. Our study
demonstrated that RPS15A was important for survival
and proliferation of glioblastoma cancer cells. In the ab-
sence of this gene, the cells underwent apoptosis
through intrinsic mitochondria pathway.
The mitochondrial pathway of apoptosis typically
involves the release of mitochondrial cytochrome c into
cytosol. The released cytochrome c combines with
apoptotic protease activating factor 1 (Apaf-1) and
procaspase-9, resulting in the activation of caspse-9 and
caspase-3 [25]. Bcl-2 plays an important role in releasing
cytochrome c from mitochondria. Our western blot re-
sult of Bcl-2 showed a significant decrease upon RPS15A
knockdown. Thus, wastage of RPS15A led to the in-
crease of anti-apoptotic signals (Bcl-2), which was in
favor of the occurrence of apoptosis. Caspase-3 cleavage
and PARP cleavage are the downstream of Bcl-2 [26, 27].
Our western blot confirmed these two cleavage events
were both enhanced upon RPS15A knockdown. These
results suggested that RPS15A knockdown induced
apoptosis mainly through the activation of mitochondrial
pathway. We hypothesize that RPS15A might be directly
involved in the translation of Bcl-2 mRNA; thus, knock-
down of RPS15A resulted in the down-regulation of Bcl-
2 protein.
Many types of cancers, including glioblastoma, are re-
sistant against many anti-cancer treatments. One of the
main reasons is that they do not activate their intracellu-
lar apoptosis pathway [28]. Current standard chemother-
apy treatment for glioblastoma is the use of alkylating
agents, temozolomide, in combination with radiation
therapy. Temozolomide has been proven somewhat
effective in prolonging survival; however, tumor often
returns after treatment, which begs the exploration of
new drugs and therapies. Our finding of induction of
apoptosis in GBM cell line by down-regulating RPS15A
provides a new avenue, which targets ribosome proteins.
Conclusions
From above analysis, we can see that RPS15A was sig-
nificantly up-regulated in GBM tissues compared with
that in normal tissues. Knockdown of RPS15A remark-
ably suppressed U251 cell growth; then, the results dem-
onstrated that RPS15A was important for survival and
proliferation of glioblastoma cancer cells. In the absence
of this gene, the cells underwent apoptosis through acti-
vation of intrinsic mitochondria pathway.
Fig. 4 Knockdown of RPS15A induces cell apoptosis via activation of mitochondrial pathway. a Representative images of cell apoptosis of U251 cells with
three treatments (shCon, shRPS15A-1, and shRPS15A-2) analyzed by flow cytometry using Annexin V/7-AAD double staining. b Statistical analysis of the
proportions of U251 cells corresponding to early (Annexin V+/7-AAD−) and late (Annexin V+/7-AAD+) apoptotic cells. c Activation of bcl-2, caspase-3, and
PARP signaling pathways measured by Western blot analysis. The experiment was performed in triplicate and repeated three times. ***p< 0.001
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In summary, our findings suggest RPS15A may play an
important role in the progression of GBM and lentiviral-
mediated silencing of RPS15A could be an effective tool
in GBM treatment.
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